effector

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

eFFECTOR, in Mission Bay Capital's portfolio, is a leader in the development of selective translation regulators for the treatment of cancer.

eFFECTOR Collaborates with Pfizer and Merck on Immuno-Oncology

eFFECTOR Collaborates with Pfizer and Merck on Immuno-Oncology

eFT508 and avelumab are immunotherapies, designed to harness the body's own immune system in fighting cancer.